Skip to content

Biotin

FDA-approved product (injectable, injection).

Registered studies
50+
Lab records
0
Pathogens at ≥40%
1 of 4

Chemical structure

Chemical structure of Biotin
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Anemia (phenotype)
  • Chronic kidney disease
  • Iron deficiency anemia
  • Type 2 diabetes mellitus

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Other plain vitamin preparations
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against K. pneumoniae. It was surfaced computationally for further investigation; it is not an established treatment for this infection.

AI-predicted activity

AI prediction · nothing measured
  • MRSA31.9% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • E. coli19.8% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae40.3% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis14.0% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

Not yet docked: queued in the docking rundetails

KPC-2 carbapenemase ↗ (K. pneumoniae)

Not yet docked: queued in the docking rundetails

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

Not yet docked: queued in the docking rundetails

Dihydrofolate reductase ↗ (MRSA)

Not yet docked: queued in the docking rundetails

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Biotin with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • BioRBC Survival in Adults With Prior Antibody Response to BioRBCs

    NCT02077751 · start 2013-05

    Registered record
    Registry ID
    NCT02077751
    Conditions
    Anemia
    Interventions
    biotin labelled RBCs
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2013-05
    Completion
    2019-12
    Enrolment
    3

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAnemia
    Interventionbiotin labelled RBCs
    PhasePhase 1
    Registry statusCompleted
  • The Effect of Methylated Vitamin B Complex on Depression

    NCT01672372 · start 2011-01

    Registered record
    Registry ID
    NCT01672372
    Conditions
    Depression
    Interventions
    Max Stress B; Placebo Max Stress B
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2011-01
    Completion
    2011-10
    Enrolment
    60

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionDepression
    InterventionMax Stress B; Placebo Max Stress B
    PhaseNot applicable
    Registry statusCompleted
  • Donor Peripheral Blood Stem Cell Transplant and Pretargeted Radioimmunotherapy in Treating Patients With High-Risk Advanced Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, or Myelodysplastic Syndrome

    NCT00988715 · start 2010-04-21

    Registered record
    Registry ID
    NCT00988715
    Conditions
    Chronic Myelomonocytic Leukemia; Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable; Previously Treated Myelodysplastic Syndrome; Recurrent Adult Acute Lymphoblastic Leukemia; Recurrent Adult Acute Myeloid Leukemia; Refractory Anemia With Excess Blasts; Refractory Cytopenia With Multilineage Dysplasia; Refractory Cytopenia With Multilineage Dysplasia and Ringed Sideroblasts; Secondary Acute Myeloid Leukemia
    Interventions
    Pretargeted Radioimmunotherapy; Cyclosporine; Mycophenolate Mofetil; Total-Body Irradiation; Nonmyeloablative Allogeneic Hematopoietic Stem Cell Transplantation; Peripheral Blood Stem Cell Transplantation; Fludarabine Phosphate; Pharmacological Study; Laboratory Biomarker Analysis
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2010-04-21
    Completion
    Not recorded
    Enrolment
    17

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionChronic Myelomonocytic Leukemia; Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable; Previously Treated Myelodysplastic Syndrome; Recurrent Adult Acute Lymphoblastic Leukemia +5 more
    InterventionPretargeted Radioimmunotherapy; Cyclosporine; Mycophenolate Mofetil; Total-Body Irradiation +5 more
    PhasePhase 1
    Registry statusCompleted
  • Efficacy of Multiple Micronutrient Fortified Biscuits and Deworming in Vietnamese School Children

    NCT00728273 · start 2007-01

    Registered record
    Registry ID
    NCT00728273
    Conditions
    Healthy
    Interventions
    worm treatment and multiple micronutrient fortified biscuits
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2007-01
    Completion
    2007-06
    Enrolment
    510

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHealthy
    Interventionworm treatment and multiple micronutrient fortified biscuits
    PhasePhase 2
    Registry statusCompleted
  • Enteral Nutrition Support in Children and Adolescents With Cancer

    NCT01426750 · start 2002-06

    Registered record
    Registry ID
    NCT01426750
    Conditions
    Malnutrition; Cancer
    Interventions
    industrialized oral supplementation (IOS) and tube feeding regimen (TFR) with Nutren
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2002-06
    Completion
    2006-06
    Enrolment
    Not recorded

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMalnutrition; Cancer
    Interventionindustrialized oral supplementation (IOS) and tube feeding regimen (TFR) with Nutren
    PhasePhase 4
    Registry statusCompleted